Impact of a cardio‐oncology unit on prevention of cardiovascular events in cancer patients
Abstract Aims As the world population grows older, the co‐existence of cancer and cardiovascular comorbidities becomes more common, complicating management of these patients. Here, we describe the impact of a large Cardio‐Oncology unit in Southern Italy, characterizing different types of patients an...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-06-01
|
| Series: | ESC Heart Failure |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/ehf2.13879 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832540296680833024 |
|---|---|
| author | Alessandra Cuomo Valentina Mercurio Gilda Varricchi Maria Rosaria Galdiero Francesca Wanda Rossi Antonio Carannante Grazia Arpino Luigi Formisano Roberto Bianco Chiara Carlomagno Carmine De Angelis Mario Giuliano Elide Matano Marco Picardi Domenico Salvatore Ferdinando De Vita Erika Martinelli Carminia Maria Della Corte Floriana Morgillo Michele Orditura Stefania Napolitano Teresa Troiani Carlo G. Tocchetti |
| author_facet | Alessandra Cuomo Valentina Mercurio Gilda Varricchi Maria Rosaria Galdiero Francesca Wanda Rossi Antonio Carannante Grazia Arpino Luigi Formisano Roberto Bianco Chiara Carlomagno Carmine De Angelis Mario Giuliano Elide Matano Marco Picardi Domenico Salvatore Ferdinando De Vita Erika Martinelli Carminia Maria Della Corte Floriana Morgillo Michele Orditura Stefania Napolitano Teresa Troiani Carlo G. Tocchetti |
| author_sort | Alessandra Cuomo |
| collection | DOAJ |
| description | Abstract Aims As the world population grows older, the co‐existence of cancer and cardiovascular comorbidities becomes more common, complicating management of these patients. Here, we describe the impact of a large Cardio‐Oncology unit in Southern Italy, characterizing different types of patients and discussing challenges in therapeutic management of cardiovascular complications. Methods and results We enrolled 231 consecutive patients referred to our Cardio‐Oncology unit from January 2015 to February 2020. Three different types were identified, according to their chemotherapeutic statuses at first visit. Type 1 included patients naïve for oncological treatments, Type 2 patients already being treated with oncological treatments, and Type 3 patients who had already completed cancer treatments. Type 2 patients presented the highest incidence of cardiovascular events (46.2% vs. 12.3% in Type 1 and 17.9% in Type 3) and withdrawals from oncological treatments (5.1% vs. none in Type 1) during the observation period. Type 2 patients presented significantly worse 48 month‐survival (32.1% vs. 16.7% in Type 1 and 17.9% in Type 3), and this was more evident when in the three groups we focused on patients with uncontrolled cardiovascular risk factors or overt cardiovascular disease at the first cardiologic assessment. Nevertheless, these patients showed the greatest benefit from our cardiovascular assessments, as witnessed by a small, but significant improvement in ejection fraction during follow‐up (Type 2b: from 50 [20; 67] to 55 [35; 65]; P = 0.04). Conclusions Patients who start oncological protocols without an accurate baseline cardiovascular evaluation are at major risk of developing cardiac complications due to antineoplastic treatments. |
| format | Article |
| id | doaj-art-006d130c84a84f1584dbd362d6c8bb14 |
| institution | Kabale University |
| issn | 2055-5822 |
| language | English |
| publishDate | 2022-06-01 |
| publisher | Wiley |
| record_format | Article |
| series | ESC Heart Failure |
| spelling | doaj-art-006d130c84a84f1584dbd362d6c8bb142025-02-05T05:22:10ZengWileyESC Heart Failure2055-58222022-06-01931666167610.1002/ehf2.13879Impact of a cardio‐oncology unit on prevention of cardiovascular events in cancer patientsAlessandra Cuomo0Valentina Mercurio1Gilda Varricchi2Maria Rosaria Galdiero3Francesca Wanda Rossi4Antonio Carannante5Grazia Arpino6Luigi Formisano7Roberto Bianco8Chiara Carlomagno9Carmine De Angelis10Mario Giuliano11Elide Matano12Marco Picardi13Domenico Salvatore14Ferdinando De Vita15Erika Martinelli16Carminia Maria Della Corte17Floriana Morgillo18Michele Orditura19Stefania Napolitano20Teresa Troiani21Carlo G. Tocchetti22Cardio‐Oncology Unit, Department of Translational Medical Sciences Federico II University Naples ItalyCardio‐Oncology Unit, Department of Translational Medical Sciences Federico II University Naples ItalyInternal Medicine and Clinical Immunology Unit, Department of Translational Medical Sciences Federico II University Naples ItalyInternal Medicine and Clinical Immunology Unit, Department of Translational Medical Sciences Federico II University Naples ItalyInternal Medicine and Clinical Immunology Unit, Department of Translational Medical Sciences Federico II University Naples ItalyCardio‐Oncology Unit, Department of Translational Medical Sciences Federico II University Naples ItalyInterdepartmental Center of Clinical and Translational Sciences (CIRCET) Federico II University Naples ItalyInterdepartmental Center of Clinical and Translational Sciences (CIRCET) Federico II University Naples ItalyInterdepartmental Center of Clinical and Translational Sciences (CIRCET) Federico II University Naples ItalyInterdepartmental Center of Clinical and Translational Sciences (CIRCET) Federico II University Naples ItalyInterdepartmental Center of Clinical and Translational Sciences (CIRCET) Federico II University Naples ItalyInterdepartmental Center of Clinical and Translational Sciences (CIRCET) Federico II University Naples ItalyDepartment of Clinical Medicine and Surgery Federico II University Naples ItalyDepartment of Clinical Medicine and Surgery Federico II University Naples ItalyDepartment of Public Health Federico II University Naples ItalyDepartment of Precision Medicine Luigi Vanvitelli University of Campania Naples ItalyDepartment of Precision Medicine Luigi Vanvitelli University of Campania Naples ItalyDepartment of Precision Medicine Luigi Vanvitelli University of Campania Naples ItalyDepartment of Precision Medicine Luigi Vanvitelli University of Campania Naples ItalyDepartment of Precision Medicine Luigi Vanvitelli University of Campania Naples ItalyDepartment of Precision Medicine Luigi Vanvitelli University of Campania Naples ItalyDepartment of Precision Medicine Luigi Vanvitelli University of Campania Naples ItalyCardio‐Oncology Unit, Department of Translational Medical Sciences Federico II University Naples ItalyAbstract Aims As the world population grows older, the co‐existence of cancer and cardiovascular comorbidities becomes more common, complicating management of these patients. Here, we describe the impact of a large Cardio‐Oncology unit in Southern Italy, characterizing different types of patients and discussing challenges in therapeutic management of cardiovascular complications. Methods and results We enrolled 231 consecutive patients referred to our Cardio‐Oncology unit from January 2015 to February 2020. Three different types were identified, according to their chemotherapeutic statuses at first visit. Type 1 included patients naïve for oncological treatments, Type 2 patients already being treated with oncological treatments, and Type 3 patients who had already completed cancer treatments. Type 2 patients presented the highest incidence of cardiovascular events (46.2% vs. 12.3% in Type 1 and 17.9% in Type 3) and withdrawals from oncological treatments (5.1% vs. none in Type 1) during the observation period. Type 2 patients presented significantly worse 48 month‐survival (32.1% vs. 16.7% in Type 1 and 17.9% in Type 3), and this was more evident when in the three groups we focused on patients with uncontrolled cardiovascular risk factors or overt cardiovascular disease at the first cardiologic assessment. Nevertheless, these patients showed the greatest benefit from our cardiovascular assessments, as witnessed by a small, but significant improvement in ejection fraction during follow‐up (Type 2b: from 50 [20; 67] to 55 [35; 65]; P = 0.04). Conclusions Patients who start oncological protocols without an accurate baseline cardiovascular evaluation are at major risk of developing cardiac complications due to antineoplastic treatments.https://doi.org/10.1002/ehf2.13879Cardio‐oncologyCardiotoxicityCardiovascular risk factorsHeart failureCancer |
| spellingShingle | Alessandra Cuomo Valentina Mercurio Gilda Varricchi Maria Rosaria Galdiero Francesca Wanda Rossi Antonio Carannante Grazia Arpino Luigi Formisano Roberto Bianco Chiara Carlomagno Carmine De Angelis Mario Giuliano Elide Matano Marco Picardi Domenico Salvatore Ferdinando De Vita Erika Martinelli Carminia Maria Della Corte Floriana Morgillo Michele Orditura Stefania Napolitano Teresa Troiani Carlo G. Tocchetti Impact of a cardio‐oncology unit on prevention of cardiovascular events in cancer patients ESC Heart Failure Cardio‐oncology Cardiotoxicity Cardiovascular risk factors Heart failure Cancer |
| title | Impact of a cardio‐oncology unit on prevention of cardiovascular events in cancer patients |
| title_full | Impact of a cardio‐oncology unit on prevention of cardiovascular events in cancer patients |
| title_fullStr | Impact of a cardio‐oncology unit on prevention of cardiovascular events in cancer patients |
| title_full_unstemmed | Impact of a cardio‐oncology unit on prevention of cardiovascular events in cancer patients |
| title_short | Impact of a cardio‐oncology unit on prevention of cardiovascular events in cancer patients |
| title_sort | impact of a cardio oncology unit on prevention of cardiovascular events in cancer patients |
| topic | Cardio‐oncology Cardiotoxicity Cardiovascular risk factors Heart failure Cancer |
| url | https://doi.org/10.1002/ehf2.13879 |
| work_keys_str_mv | AT alessandracuomo impactofacardiooncologyunitonpreventionofcardiovasculareventsincancerpatients AT valentinamercurio impactofacardiooncologyunitonpreventionofcardiovasculareventsincancerpatients AT gildavarricchi impactofacardiooncologyunitonpreventionofcardiovasculareventsincancerpatients AT mariarosariagaldiero impactofacardiooncologyunitonpreventionofcardiovasculareventsincancerpatients AT francescawandarossi impactofacardiooncologyunitonpreventionofcardiovasculareventsincancerpatients AT antoniocarannante impactofacardiooncologyunitonpreventionofcardiovasculareventsincancerpatients AT graziaarpino impactofacardiooncologyunitonpreventionofcardiovasculareventsincancerpatients AT luigiformisano impactofacardiooncologyunitonpreventionofcardiovasculareventsincancerpatients AT robertobianco impactofacardiooncologyunitonpreventionofcardiovasculareventsincancerpatients AT chiaracarlomagno impactofacardiooncologyunitonpreventionofcardiovasculareventsincancerpatients AT carminedeangelis impactofacardiooncologyunitonpreventionofcardiovasculareventsincancerpatients AT mariogiuliano impactofacardiooncologyunitonpreventionofcardiovasculareventsincancerpatients AT elidematano impactofacardiooncologyunitonpreventionofcardiovasculareventsincancerpatients AT marcopicardi impactofacardiooncologyunitonpreventionofcardiovasculareventsincancerpatients AT domenicosalvatore impactofacardiooncologyunitonpreventionofcardiovasculareventsincancerpatients AT ferdinandodevita impactofacardiooncologyunitonpreventionofcardiovasculareventsincancerpatients AT erikamartinelli impactofacardiooncologyunitonpreventionofcardiovasculareventsincancerpatients AT carminiamariadellacorte impactofacardiooncologyunitonpreventionofcardiovasculareventsincancerpatients AT florianamorgillo impactofacardiooncologyunitonpreventionofcardiovasculareventsincancerpatients AT micheleorditura impactofacardiooncologyunitonpreventionofcardiovasculareventsincancerpatients AT stefanianapolitano impactofacardiooncologyunitonpreventionofcardiovasculareventsincancerpatients AT teresatroiani impactofacardiooncologyunitonpreventionofcardiovasculareventsincancerpatients AT carlogtocchetti impactofacardiooncologyunitonpreventionofcardiovasculareventsincancerpatients |